Last updated: 2026-09-06 03:09:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Vistagen Therapeutics, Inc. (VTGN) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $0.24, with a market capitalization of $10.92M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.20 to $5.14. This page covers its latest market performance, valuation, price trends and company information.
$10.92M | |
$0.25 | |
$140.70 | |
$0.20 | |
$0.25 | |
344.59K | |
-- | |
-- | |
$5.14 | |
$0.20 | |
-- | |
-- |
Vistagen Therapeutics, Inc. (VTGN) last closed at $0.25 as of 2026-09-04 23:57:00, unchanged from the previous close of $0.25.
During the latest regular trading session, VTGN traded between $0.20 and $140.70, with a volume of 344.59K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, Vistagen Therapeutics, Inc. (VTGN) moved from $0.26 to $0.24, representing a decline of 5.43% ($0.01).
The stock traded between $0.24 and $0.26 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 379.47 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 0.9%
VTGN is currently trading at $0.24, placing it 0.9% of the way from its 52-week low of $0.20 to its 52-week high of $5.14. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Vistagen Therapeutics Inc is a late clinical-stage therapeutics company focused on developing and commercializing medicines for patients with social anxiety disorder, depression, menopausal hot flashes, psychomotor impairment due to mental fatigue, and cancer cachexia. The company is engaged in developing intranasal product candidates called pherines, which leverage the understanding of nose-to-brain neurocircuitry. Vistagen's pherine pipeline consists of various product candidates like: Fasedienol, Itruvone, PH15, Refisolone, and PH284, which are being developed to provide treatment for a variety of disorders. Additionally, it is seeking potential partners for the further clinical development and commercialization of an oral drug candidate, AV-101, to treat certain neurological disorders.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 41 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Vistagen Therapeutics, Inc. (VTGN) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.